Table 2.

Completed or current ongoing clinical trials with T- and B-cell peptide vaccines

T-cell peptide vaccines
Examined vaccine	Phase	Adjuvant	Systemic intervention	Patients	Setting	NCT/trial’s identifier	Reference
E75	I	GM-CSF	None	Breast cancer	Experimental (vaccine) versus no intervention (control)	NCT00841399	88
	I	GM-CSF	None	Breast cancer	Experimental (vaccine) versus no intervention (control)	NCT00854789	88
	II	GM-CSF	Trastuzumab	Breast cancer	Vaccine + trastuzumab versus trastuzumab + GM-CSF	NCT01570036	89
	III	GM-CSF	None	Breast cancer (low to intermediate Her-2/neu expression)	Vaccine versus GM-CSF only	NCT01479244	90
	II	GM-CSF	None	Breast cancer	Vaccine versus GM-CSF only	NCT02636582	88
	II	GM-CSF	Trastuzumab	Breast cancer	Vaccine + trastuzumab versus trastuzumab + GM.-CSF	NCT02297698	88
GP2	I	GM-CSF	None	Breast cancer	Dose escalation	#11 730a	92
	II	GM-CSF	None	Breast cancer	Vaccine versus GM-CSF only	NCT00524277	93
	Ib	GM-CSF	Trastuzumab	Breast cancer	Vaccine + trastuzumab versus trastuzumab	NCT03014076	94
AE37	I	GM-CSF	None	Breast cancer	Dose escalation	#12 229a	95
	II	GM-CSF	None	Breast cancer	Vaccine versus GM-CSF only	NCT00524277	96
HER2/neu peptide	I/II	Breast and ovarian cancers	Trastuzumab	Breast or ovarian cancer	Active, not recruiting	NCT00194714	98

B-cell peptide vaccines
Examined vaccine	Phase	Adjuvant	Systemic intervention	Patients	Setting	NCT/trial’s identifier	Reference
HER-Vaxx (IMU-131)	Ib	Montanide	Chemotherapy	Her-2 + gastric cancer	Dose escalation		77
	II	Montanide	Chemotherapy	Her-2 + gastric cancer	Vaccine + chemotherapy versus chemotherapy alone		Ongoing study
B-vaxx	I		None	Metastatic solid tumors	Dose escalation		102
	II		None	Metastatic solid tumors (breast, ovarian and gastrointestinal cancers)	Extension trial		Ongoing study

GM-CSF, granulocyte–macrophage colony-stimulating factor.

^aWalter Reed Army Medical Center.